Business Description
Cidara Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1717571079
Description
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 32.31 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.09 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.96 | |||||
| Beneish M-Score | 1.26 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 36 | |||||
| 3-Year EBITDA Growth Rate | 45.3 | |||||
| 3-Year EPS without NRI Growth Rate | 47.5 | |||||
| 3-Year FCF Growth Rate | 41.5 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.98 | |||||
| 9-Day RSI | 63.67 | |||||
| 14-Day RSI | 65.1 | |||||
| 6-1 Month Momentum % | 88.35 | |||||
| 12-1 Month Momentum % | 24.49 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.54 | |||||
| Quick Ratio | 3.54 | |||||
| Cash Ratio | 2.87 | |||||
| Days Inventory | 56.96 | |||||
| Days Sales Outstanding | 42.6 | |||||
| Days Payable | 45.46 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.4 | |||||
| Shareholder Yield % | -94.73 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 45.35 | |||||
| Operating Margin % | -86.9 | |||||
| Net Margin % | -231.54 | |||||
| FCF Margin % | -308.35 | |||||
| ROE % | -264.05 | |||||
| ROA % | -116.34 | |||||
| ROIC % | -185.07 | |||||
| ROC (Joel Greenblatt) % | -955.26 | |||||
| ROCE % | -85.02 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2.02 | |||||
| PB Ratio | 1.42 | |||||
| Price-to-Tangible-Book | 1.42 | |||||
| EV-to-EBIT | -2.88 | |||||
| EV-to-EBITDA | -2.9 | |||||
| EV-to-Revenue | 2.51 | |||||
| EV-to-Forward-Revenue | 0.69 | |||||
| EV-to-FCF | -0.82 | |||||
| Price-to-Net-Current-Asset-Value | 1.49 | |||||
| Price-to-Net-Cash | 2.03 | |||||
| Earnings Yield (Greenblatt) % | -34.72 | |||||
| FCF Yield % | -63.01 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cidara Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 47.845 | ||
| EPS (TTM) (€) | -23.463 | ||
| Beta | 1.47 | ||
| Volatility % | 87.9 | ||
| 14-Day RSI | 65.1 | ||
| 14-Day ATR (€) | 0.820743 | ||
| 20-Day SMA (€) | 20.195 | ||
| 12-1 Month Momentum % | 24.49 | ||
| 52-Week Range (€) | 9.464 - 22.28 | ||
| Shares Outstanding (Mil) | 10.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cidara Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cidara Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cidara Therapeutics Inc Frequently Asked Questions
What is Cidara Therapeutics Inc(STU:20D0)'s stock price today?
The current price of STU:20D0 is €21.40. The 52 week high of STU:20D0 is €22.28 and 52 week low is €9.46.
When is next earnings date of Cidara Therapeutics Inc(STU:20D0)?
The next earnings date of Cidara Therapeutics Inc(STU:20D0) is 2025-04-22 Est..
Does Cidara Therapeutics Inc(STU:20D0) pay dividends? If so, how much?
Cidara Therapeutics Inc(STU:20D0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers